A Randomized, Open-label, Single-Dose, 2-Treatment, 2-Way, 2-Period Crossover Study to Compare the Safety and the Pharmacokinetic Characteristics of Mosapride/Rebamipide Combination Tablet with Mosapride and Rebamipide Tablet in Healthy Male Korean Subjects

Trial Profile

A Randomized, Open-label, Single-Dose, 2-Treatment, 2-Way, 2-Period Crossover Study to Compare the Safety and the Pharmacokinetic Characteristics of Mosapride/Rebamipide Combination Tablet with Mosapride and Rebamipide Tablet in Healthy Male Korean Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

At a glance

  • Drugs Mosapride/rebamipide (Primary) ; Mosapride; Rebamipide
  • Indications Dyspepsia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 25 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top